Clinical and Epidemiological Aspects of Clostridium difficile

Clinical Microbiology Newsletter

Volumn 30, Issue 12, 2008, Pages 87-95

  Oughton, Matthew T ^a   Miller, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; RAMOPLANIN; RIFAXIMIN; TIACUMICIN B; TOLEVAMER; VANCOMYCIN;

ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CLOSTRIDIUM DIFFICILE; DIAGNOSTIC TEST; DISEASE SEVERITY; EARLY DIAGNOSIS; ENVIRONMENTAL SANITATION; EPIDEMIOLOGICAL DATA; EUROPE; FECES MICROFLORA; HUMAN; HYGIENE; INFECTION CONTROL; MOLECULAR BIOLOGY; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MORBIDITY; MORTALITY; NONHUMAN; NORTH AMERICA; POLYMERASE CHAIN REACTION; PROGNOSIS; RELAPSE; STRAIN DIFFERENCE; TREATMENT FAILURE;

EID: 44449118907     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2008.05.004     Document Type: Article

References (116)

1. Archibald L.K., Banerjee S.N., and Jarvis W.R. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J. Infect. Dis. 189 (2004) 1585-1589
2. Ricciardi R., et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch. Surg. 142 (2007) 624-631
3. Redelings M.D., Sorvillo F., and Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg. Infect. Dis. 13 (2007) 1417-1419
4. Centers for Disease Control and Prevention. Data and statistics about Clostridium difficile infections (2007). http://www.cdc.gov/ncidod/dhqp/id_Cdiff_data.html
5. McDonald L.C., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353 (2005) 2433-2441
6. Tan E.T., et al. Clostridium difficile-associated disease in New Jersey hospitals, 2000-2004. Emerg. Infect. Dis. 13 (2007) 498-500
7. Kyne L., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34 (2002) 346-353
8. Chernak E., et al. Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb. Mortal. Wkly. Rep. 54 (2005) 1201-1205
9. Miller M.A., et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect. Contr. Hosp. Epidemiol. 23 (2002) 137-140
10. Eggertson L., and Sibbald B. Hospitals battling outbreaks of C. difficile. CMAJ 171 (2004) 19-21
11. Weiss K., et al. Clostridium difficile-associated diarrhoea rates and global antibiotic consumption in five Quebec institutions from 2001 to 2004. Int. J. Antimicrob. Agents 30 (2007) 309-314
12. Loo V.G., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353 (2005) 2442-2449
13. Hubert B., et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin. Infect. Dis. 44 (2007) 238-244
14. Pepin J., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171 (2004) 466-472
15. Pepin J., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40 (2005) 1591-1597
16. MacCannell D.R., et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from eastern and western Canada. J. Clin. Microbiol. 44 (2006) 2147-2152
17. Canadian Nosocomial Infection Surveillance Program. Clostridium difficile associated disease (CDAD) surveillance: 2004-2005 (2007). http://www.phac-aspc.gc.ca/nois-sinp/projects/cdad_e.html
18. Kuijper E.J., Coignard B., and Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12 (2006) 2-18
19. Kuijper E.J., et al. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill. 12 (2007) E1-E2
20. Lyytikäinen O., et al. 2007. First isolation of Clostridium difficile PCR ribotype 027 in Finland. Euro Surveill. E071108.2
21. Bouvet, P. 2006. Personal communication, M. Oughton (Ed.). Montreal.
22. Carlier J.P. Catalogue data sheet of Clostridium difficile CIP 107932. 2007 (2003). http://www.crbip.pasteur.fr/fiches/fichecata.jsp?crbip=107932
23. Popoff M.R., et al. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect. Immun. 56 (1988) 2299-2306
24. Mutlu E., et al. Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J. Med. Microbiol. 56 (2007) 921-929
25. Wilcox M.H., et al. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J. Antimicrob. Chemother. 46 (2000) 551-556
26. Goorhuis A., et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin. Infect. Dis. 45 (2007) 695-703
27. Alonso R., et al. In vitro activity of new quinolones against Clostridium difficile. J. Antimicrob. Chemother. 47 (2001) 195-197
28. Pituch H., et al. Toxin profiles and resistances to macrolides and newer fluoroquinolones as epidemicity determinants of clinical isolates of Clostridium difficile from Warsaw, Poland. J. Clin. Microbiol. 45 (2007) 1607-1610
29. Rupnik M., et al. New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J. Clin. Microbiol. 41 (2003) 1118-1125
30. Sawabe E., et al. Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. Eur. J. Clin. Microbiol. Infect. Dis. 26 (2007) 695-703
31. Kato, H. et al. 2007. First isolation of Clostridium difficile 027 in Japan. Euro Surveill. E070111.3
32. Bidet P., et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J. Clin. Microbiol. 38 (2000) 2484-2487
33. Clabots C.R., et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J. Clin. Microbiol. 31 (1993) 1870-1875
34. Delmee M., et al. Comparison of serogrouping and polyacrylamide gel electrophoresis for typing Clostridium difficile. J. Clin. Microbiol. 24 (1986) 991-994
35. Klaassen C.H.W., van Haren H.A., and Horrevorts A.M. Molecular fingerprinting of Clostridium difficile isolates: pulsed-field gel electrophoresis versus amplified fragment length polymorphism. J. Clin. Microbiol. 40 (2002) 101-104
36. Kristjansson M., et al. Comparison of restriction endonuclease analysis, ribotyping, and pulsed-field gel electrophoresis for molecular differentiation of Clostridium difficile strains. J. Clin. Microbiol. 32 (1994) 1963-1969
37. O'Neill G.L., et al. A comparison of PCR ribotyping and pyrolysis mass spectrometry for typing clinical isolates of Clostridium difficile. Anaerobe 2 (1996) 211-215
38. Poilane I., et al. Molecular characterization of Clostridium difficile clinical isolates in a geriatric hospital. J. Med. Microbiol. 56 (2007) 386-390
39. Wust J., et al. Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J. Clin. Microbiol. 16 (1982) 1096-1101
40. Brazier J.S., et al. Preliminary findings of the international typing study on Clostridium difficile. Clin. Infect. Dis. 25 Suppl. 2 (1997) S199-S201
41. Brazier J.S. Typing of Clostridium difficile. Clin. Microbiol. Infect. 7 (2001) 428-431
42. Nakamura S., et al. Isolation of Clostridium difficile from feces and the antibody in sera of young and elderly adults. Microbiol. Immunol. 25 (1981) 345-351
43. Sell T.L., Schaberg D.R., and Fekety F.R. Bacteriophage and bacteriocin typing scheme for Clostridium difficile. J. Clin. Microbiol. 17 (1983) 1148-1152
44. Tabaqchali S., et al. Typing scheme for Clostridium difficile: its application in clinical and epidemiological studies. Lancet 323 (1984) 935-938
45. Spigaglia P., et al. Molecular typing and long-term comparison of Clostridium difficile strains by pulsed-field gel electrophoresis and PCR-ribotyping. J. Med. Microbiol. 50 (2001) 407-414
46. Gürtler V. Typing of Clostridium difficile strains by PCR amplification of variable length 16S-23S rDNA spacer regions. J. Gen. Microbiol. 139 (1993) 3089-3097
47. O'Neill G.L., et al. Modification of a PCR ribotyping method for application as a routine typing scheme for Clostridium difficile. Anaerobe 2 (1996) 205-209
48. Marsh J.W., et al. Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in hospitals. J. Clin. Microbiol. 44 (2006) 2558-2566
49. Rupnik M., et al. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J. Clin. Microbiol. 36 (1998) 2240-2247
50. Rupnik M., et al. Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology 147 (2001) 439-447
51. Sebaihia M., et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat. Genet. 38 (2006) 779-786
52. Forgetta V. et al. 2007. Developing genome resources for Clostridium difficile. In 2020 vision: adaptation to environmental change (Genome Canada International Conference, 2007). Genome Canada, Quebec City, Quebec, Canada.
53. Maiden M.C.J., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. USA 95 (1998) 3140-3145
54. Lemee L., et al. Multilocus sequence typing analysis of human and animal Clostridium difficile iso-lates of various toxigenic types. J. Clin. Microbiol. 42 (2004) 2609-2617
55. Lemee L., et al. Multilocus sequence analysis and comparative evolution of virulence-associated genes and housekeeping genes of Clostridium difficile. Microbiology 151 (2005) 3171-3180
56. van den Berg R.J., et al. Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J. Clin. Microbiol. 45 (2007) 1024-1028
57. Delmee M., et al. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J. Med. Microbiol. 54 (2005) 187-191
58. Reller M.E., et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J. Clin. Microbiol. 45 (2007) 3601-3605
59. Bouza E., et al. "Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. J. Hosp. Infect. 48 (2001) 233-237
60. Borriello S.P., et al. Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect. Immun. 60 (1992) 4192-4199
61. Rupnik M. How to detect Clostridium difficile variant strains in a routine laboratory. Clin. Microbiol. Infect. 7 (2001) 417-420
62. Alfa M.J., et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38 (2000) 2706-2714
63. Kato H., et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J. Clin. Microbiol. 36 (1998) 2178-2182
64. Sambol S.P., et al. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect. Immun. 68 (2000) 5480-5487
65. Blake J.E., Mitsikosta F., and Metcalfe M.A. Immunological detection and cytotoxic properties of toxins from toxin A-positive, toxin B-positive Clostridium difficile variants. J. Med. Microbiol. 53 (2004) 197-205
66. Barbut F., et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin. Microbiol. Infect. 9 (2003) 989-996
67. Robert Michael Educational Institute. 2007. Clostridium difficile-associated disease: a focus on clinical presentation and diagnosis. CME Newslett. 1:Sept. Available online at http://www.rmei.com/CDAD509/.
68. Wilkins T.D., and Lyerly D.M. Clostridium difficile testing: after 20 years, still challenging. J. Clin. Microbiol. 41 (2003) 531-534
69. Musher D.M., et al. Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. J. Clin. Microbiol. 45 (2007) 2737-2739
70. Turgeon D.K., et al. Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J. Clin. Microbiol. 41 (2003) 667-670
71. Belanger S.D., et al. Rapid detection of Clostridium difficile in feces by real-time PCR. J. Clin. Microbiol. 41 (2003) 730-734
72. van den Berg R.J., et al. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. J. Med. Microbiol. 56 (2007) 36-42
73. Peterson L.R., et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin. Infect. Dis. 45 (2007) 1152-1160
74. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am. J. Gastroenterol. 92 (1997) 739-750
75. Boyce J.M., and Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect. Contr. Hosp. Epidemiol. 23 (2002) S3-S40
76. King S. Provision of alcohol hand rub at the hospital bedside: a case study. J. Hosp. Infect. 56 Suppl. 2 (2004) 10-12
77. Oughton, M. et al. 2007. Alcohol rub and antiseptic wipes are inferior to soap and water for removal of Clostridium difficile by handwashing, abstr. no. K-1376a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17-20 September, 2007. American Society for Microbiology, Washington, DC.
78. Boyce J.M., et al. Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. Infect. Contr. Hosp. Epidemiol. 27 (2006) 479-483
79. Dendukuri N., et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 173 (2005) 167-170
80. Sougioultzis S., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128 (2005) 764-770
81. Anonymous. American Society of Hospital Pharmacists' therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am. J. Health Syst. Pharm. 55 (1998) 1407-1411
82. Wenisch C., et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 23 (1996) 813-818
83. Teasley D.G., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 322 (1983) 1043-1046
84. Belmares J., et al. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J. Infect. 55 (2007) 495-501
85. Zar F.A., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45 (2007) 302-307
86. Louie, T. et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD), abstr. no. K-425a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17-20 September, 2007. American Society for Microbiology, Washington, DC.
87. Bolton R.P., and Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27 (1986) 1169-1172
88. Keighley M.R., et al. Random-ised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br. Med. J. 2 (1978) 1667-1669
89. Apisarnthanarak A., Razavi B., and Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin. Infect. Dis. 35 (2002) 690-696
90. Surowiec D., et al. Past, present, and future therapies for Clostridium difficile-associated disease. Ann. Pharmacother 40 (2006) 2155-2163 10.1345/aph.1H332
91. Shetler K., et al. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg. Endosc. 15 (2001) 653-659
92. Nelson, R. 2007. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. Issue 3, Article no. CD004610. DOI:10.1002/14651858.CD004610.pub3.
93. Berenbaum P.L. Oral rifaximin in treatment of Clostridium difficile-associated diarrhea. Am. J. Gastroenterol. 101 (2006) S199
94. Johnson S., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44 (2007) 846-848
95. Galang M.A., et al. 2007. Rifampin susceptibility by agar dilution and Etest predicts susceptibility to rifaximin in Clostridium difficile, abstr. no. K-425. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17-20 September, 2007. American Society for Microbiology, Washington, D.C.
96. DuPont H.L., et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann. Intern. Med. 142 (2005) 805-812
97. Musher D.M., et al. Nitazoxanide for the treatment of Clostridium difficile Colitis. Clin. Infect. Dis. 43 (2006) 421-427
98. Young J.D., et al. Nitazoxanide versus metronidazole for Clostridium difficile-associated colitis. Clin. Infect. Dis. 44 (2007) 152
99. Farver D.K., Hedge D.D., and Lee S.C. Ramoplanin: a lipoglycodepsipeptide antibiotic. Ann. Pharmacother. 39 (2005) 863-868
100. Leach, T., J. Pullman, and J. Prieto. 2004. Ramoplanin vs. vancomycin in the treatment of Clostridium difficile diarrhea: a phase 2 study, abstr. no. K-985a. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC., 30 October to 4 November, 2004. American Society for Microbiology, Washington, DC.
101. Ackermann G., et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob. Agents Chemother. 48 (2004) 2280-2282
102. Louie, T. et al. 2005. Safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects and patients with Clostridium difficile-associated diarrhea (CDAD), abstr. no. LB2-29. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC., 16-19 December, 2005. American Society for Microbiology, Washington, DC.
103. Jodlowski T.Z., et al. Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother. 40 (2006) 2164-2169
104. McPherson S., et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis. Colon Rectum 49 (2006) 640-645
105. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 53 (2004) 882-884
106. McFarland L.V., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271 (1994) 1913-1918
107. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 10 (2006) 812-822
108. Dendukuri N., and Brophy J. Inappropriate use of meta-analysis to estimate efficacy of probiotics. Am. J. Gastroenterol. 102 (2007) 201
109. Hickson M., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335 (2007) 80 10.1136/bmj.39231.599815.55
110. Wilcox M.H., and Sandoe J.A. Results of study of probiotic yoghurt drink to prevent antibiotic-associated diarrhoea are not widely applicable. Br. Med. J. 335 (2007) 171 (Letter.)
111. Schwan A., et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand. J. Infect. Dis. 16 (1984) 211-215
112. Wettstein, A.R. et al. 2007. Fecal bacteriotherapy - an effective treatment for relapsing symptomatic Clostridium difficile infection, abstr. no. G-67. Abstr. 15th United European Gastroenterology Week (UEGW) 2007, United European Gastroenterology Federation, Paris, France.
113. Aas J., Gessert C.E., and Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36 (2003) 580-585
114. Tvede M., and Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 333 (1989) 1156-1160
115. Koss K., et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 8 (2006) 149-154
116. Haeck, O. et al. 2005. Risk factors for mortality among patients with severe Clostridium difficile-associated diarrhea (CDAD) in two tertiary care hospitals in Quebec (2003-2004), abstr. No. K1267. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC. 16-19 December, 2005. American Society for Microbiology, Washington, DC.